News Archive

EMA - Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023

13th November 2023

Meeting highlights

Read More+

EMA - CTIS newsflash

13th November 2023

10th November 2023

Read More+

EMA - Call for expression of interest for independent scientific experts to participate in the work of EMA’s Safety Committee

13th November 2023

The European Commission is launching a selection procedure to appoint independent scientific experts to EMA’s Pharmacovigilance Risk Assessment Committee (PRAC). Six experts will be appointed for a three-year mandate starting on 2 July 2024.

Read More+

EMA - Global regulators celebrate 10 years of strategic leadership and cooperation

13th November 2023

This year marks the 10th anniversary of the International Coalition of Medicines Regulatory Authorities (ICMRA).

Read More+

EMA - Human Medicines Highlights Oct 2023

13th November 2023

Issue 174

Read More+

EMA - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)

13th November 2023

6-9 November 2023

Read More+

EMA - Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP)

13th November 2023

7-9 November 2023

Read More+

FDA - Benefit-Risk Assessment for New Drug and Biological Products

13th November 2023

The FDA has published its final guidance on Benefit-Risk Assessment (BRA), which clarifies how these considerations factor into FDA's regulatory decisions.

Read More+

ICH - Assembly Meeting, Prague, Czech Republic, October/November 2023

13th November 2023

The Assembly of the International Council for Harmonisation (ICH) met in-person on 31 October & 1 November 2023, in Prague, Czech Republic in parallel of meetings of 16 Working Groups, and preceded by meetings of the ICH Management Committee and the MedDRA Management Committee.

Read More+

MHRA Blog - The role of genetics in medicine safety

13th November 2023

Dr Alison Cave, Chief Safety Officer at the Medicines and Healthcare products Regulatory Agency (MHRA) highlights how genetics could play an important role in minimising the risk of adverse drug reactions (ADRs), and how the MHRA are working with partners across the system to make this a reality with their new Yellow Card biobank.

Read More+